Fresenius Kabi Succeeds In Canadian Adalimumab Tussle
Court Order Provides For Immediate Marketing Authorization
Fresenius Kabi has been forced to wait to gain a Notice of Compliance, effectively a marketing authorization, for its Idacio (adalimumab) biosimilar to Humira in Canada, in light of the Minister of Health’s interpretation of regulatory language. However, a Federal Court has now found that earlier decisions by the Ministry barring approval were unreasonable.
You may also be interested in...
Sandoz Confirms Launch Of Humira Rival In Canada
Sandoz has confirmed the launch of its Hyrimoz biosimilar rival to Humira in Canada, with other biosimilars firms having also set their sights on a mid-February launch.
What’s Next? Five Things To Look Out For In February
In the month ahead, Amarin is likely to reveal the latest on its plans to petition the US Supreme Court over generic versions of Vascepa, while biosimilar competition to Humira is set to arrive and the bulk of fourth-quarter and year-end financial results will emerge.
Slovenia Is Our Commitment; Evotec Is A Gamechanger: Sandoz’s Stenico
On the sidelines of Medicines for Europe’s 19th biosimilar conference in Amsterdam, Sandoz global biosimilars chief Peter Stenico spoke to Generics Bulletin about the firm’s preparations and strategy ahead of its proposed spinoff from Novartis later this year.